Abstract 374P
Background
European guidelines recommend endocrine therapy (ET) with CDK4/6 inhibitors (CDK4/6i) as the standard of care for HR+/HER2- (immunohistochemistry [IHC] 0, 1+, 2+/in situ IHC-) mBC. Despite its efficacy, most pts develop ET resistance, after which treatment (Tx) options are limited to CT. Antibody-drug conjugates have recently been added as Tx option in later lines. This study described patient characteristics, Tx patterns and survival outcomes of HR+/HER2- mBC pts initiating CT using Rw data from France and Germany, separately.
Methods
HR+/HER2- mBC adults from the Institut de Cancérologie de l'Ouest, France, Charité Universitätsmedizin Berlin and Würzburg University Hospital, Germany, who started 1st CT for mBC from Jan 2016 to Feb 2023, were analysed. Baseline characteristics and Txs were described using descriptive statistics. Kaplan-Meier method was used to describe Rw overall survival (OS) from start of each line for 1st to 4th CT line.
Results
The study included 339 patients from France and 157 patients from Germany. Of the German cohort: 99% were female, 32% had de novo mBC, with median age of 57 years at 1st CT. Prior to 1st CT start, 43% received CDK4/6i and ET for mBC. 59%, 32% and 15% had records of subsequent 2nd, 3rd and 4th CT line, respectively, mostly as monotherapy. Median RwOS was 23.5, 12.7, 9.6 and 6.7 months from 1st, 2nd, 3rd and 4th CT line, respectively (Table). The German results presented are aligned with those observed and previously presented for France1. 1 Campone M et al. ESMO BC Congress 2024, Berlin.
Conclusions
HR+/HER2- mBC pts initiating CT in France and Germany showed poor prognosis with median survival decreasing with each subsequent CT line. The consistent findings in both countries demonstrate continued high unmet need for improved treatment options for this population in Europe. Table: 374P
RwOS by CT line
1st CT | 2nd CT | 3rd CT | 4th CT | ||
N Pts | 157 | 92 | 51 | 23 | |
N Deaths | 75 | 46 | 25 | 11 | |
Median rwOS in months (mo) (IQR) | 23.5 (9.0-NR) | 12.7 (6.2-NR) | 9.6 (4.9-NR) | 6.7 (2.3-NR) | |
6 mo | N | 110 | 58 | 30 | - |
% Survival [95% CI] | 82% [76-89] | 76% [67-86] | 73% [62-88] | - | |
12 mo | N | 76 | 29 | 10 | - |
% Survival [95% CI] | 66% [59-75] | 54% [43-67] | 42% [29-62] | - | |
18 mo | N | 55 | 19 | - | - |
% Survival [95% CI] | 57% [49-67] | 40% [29-54] | - | ||
24 mo | N | 39 | 12 | - | - |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gilead Sciences, Inc.
Funding
Gilead Sciences, Inc.
Disclosure
M. Campone: Financial Interests, Institutional, Advisory Board: Astrazeneca, Novartis, Sanofi, Daiichi Sankyo, Lilly, Stemline, Gilead, Seagen; Financial Interests, Institutional, Invited Speaker: Novartis, Lilly. J. Frenel: Financial Interests, Personal, Advisory Board: Pfizer, Novocure, Pierre Fabre, Eisai, Seagen, Gilead; Financial Interests, Personal, Invited Speaker: GSK, Amgen, Eisai; Financial Interests, Institutional, Advisory Board: Exactscience, Lilly, Daiichi Sankyo, AstraZeneca, Clovis Oncology; Financial Interests, Institutional, Invited Speaker: Novartis, MSD; Financial Interests, Coordinating PI: AstraZeneca, Seagen; Financial Interests, Local PI: MSD, Daiichi Sankyo; Non-Financial Interests, Principal Investigator: Novartis, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD. V.I.I. Kiver: Financial Interests, Personal, Advisory Board: Gilead, Lilly; Financial Interests, Personal, Invited Speaker: Novartis, Pfizer, Roche, Eisei, AstraZeneca; Financial Interests, Personal and Institutional, Research Grant: Novartis; Non-Financial Interests, Principal Investigator: Novartis, Pfizer, AstraZeneca; Non-Financial Interests, Personal, Training: Novartis. A. Woeckel: Financial Interests, Personal, Advisory Board: AstraZeneca, • Novartis, Pfizer, Roche, MSD, Stemline; Financial Interests, Personal, Invited Speaker: Lilly, Novartis, Pfizer, Gilead, Dajichi Sanko. A.G. Kerscher: Financial Interests, Institutional, Other, IT-Infrastructure: Janssen; Other, Consulting: IQVIA. M. Krebs: Financial Interests, Personal, Advisory Board: Janssen, IQVIA, GSK Oncology; Financial Interests, Personal, Stocks/Shares: General Electric. C.S. Leal: Financial Interests, Personal, Full or part-time Employment, Epidemiologist: IQVIA. V.M. Saglimbene: Financial Interests, Personal, Full or part-time Employment: IQVIA Solutions. N. Trankov: Financial Interests, Personal, Full or part-time Employment: IQVIA. N. Sadetsky: Financial Interests, Personal, Full or part-time Employment: Gilead; Financial Interests, Personal, Stocks/Shares: gilead, Roche/Genentech. N. Sjekloca: Financial Interests, Personal, Stocks or ownership: Gilead Sciences Europe Ltd.; Financial Interests, Personal, Full or part-time Employment: Gilead Sciences Europe Ltd. O. Libert: Financial Interests, Personal, Full or part-time Employment, Medical Affairs: Gilead Sciences; Financial Interests, Personal, Stocks/Shares: Gilead Sciences. A.G. Kaushik: Financial Interests, Institutional, Full or part-time Employment: Employee of Gilead Sciences; Financial Interests, Institutional, Stocks/Shares: Stockholder of Gilead Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
414P - The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis
Presenter: Brenno Pastò
Session: Poster session 15
415P - Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer
Presenter: Eleonora Nicolo
Session: Poster session 15
417P - EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project
Presenter: Claudia Omarini
Session: Poster session 15
418P - Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
Presenter: Charlton Tsai
Session: Poster session 15
419P - Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer
Presenter: Ankur Bahl
Session: Poster session 15
420P - An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples
Presenter: Sarah Statt
Session: Poster session 15
421P - Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 15
422P - Disparities in treatment delays among metastatic breast cancer patients: Insights from nationwide electronic health records, 2011-2022
Presenter: Asal Pilehvari
Session: Poster session 15
423P - Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada
Presenter: Priya Thomas
Session: Poster session 15